Ovarian Cancer
Conditions
Keywords
tumor organoids, drug sensitivity, precision treatment
Brief summary
The tumor organoids platform can provide the precise genetic information and phenotype, as well as the heterogeneity of the tumor, thus provide information on drug sensitivity specific to the patient.This is an exploratory research to see if organoids testing could help guide precision treatment for ovarian cancer(OC) patients.
Detailed description
Tissue will be received from operative specimens( primary ovarian carcinoma) at time of primary cytoreductive surgery.Ovarian cancer(OC) organoids will be then cultured. Organoids will be validated with a combination of Next Generation Sequencing (NGS) analysis and immunohistochemistry (TP53, PAX8 etc). After then, the patient-derived organoids cultured from OC will be compared the sensitivity to standard regimens (chemotherapies and targeted agents) recommendated by NCCN guidlines versus patients treated in clinical practice.
Interventions
OTHERno intervention
It is an observation trial.
Sponsors
Chongqing University Cancer Hospital
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Inclusion criteria
1. Ovarian cancer patients who will accept primary cytoreductive surgery, with histopathological type: low/high grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma. 2. ECOG score 0\ 1,age 18\ 70 years old 3. Expected survival over 6 months 4. The serum or urine pregnancy test must be negative within 7 days before enrollment for the women of childbearing age who should agree that contraception must be used during the trial 5. CBC：Hb≥70g/L、WBC≥3.5×109/ L 、ANC≥1.5×109/L、PLT≥80×109/L； 6. Serum ALT≤2×UL, AST≤2×ULN；Serum creatinine≤1.5×ULN；
Exclusion criteria
1. Activity or uncontrol severe infection 2. Liver cirrhosis, Decompensated liver disease 3. History of immune deficiency, including HIV positive or suffering from congenital immunodeficiency disease 4. Chronic renal insufficiency or renal failure 5. Has combined with other malignant tumor which diagnosed within 5 years and/or needed to be treated 6. Myocardial infarction, severe arrhythmia and NYHA (New York heart association)≥2 for congestive heart failure 7. During the treatment for complications, the drugs which lead to serious liver and/or kidney function impairment need to be used, such as tuberculosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 5 years | Progression-free survival |
| OS | 5 years | Overall survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | 1 year | CR+PR |
| DCR | 1 year | CR+PR+SD |
Countries
China
Contacts
Primary ContactDongling Zou, M.D.
Outcome results
None listed